As Lilly, Innovent hit FDA rebuff, another China-made PD-1 cancer drug faces possible delay

After the FDA snubbed Eli Lilly and Innovent Biologics’ cancer immunotherapy sintilimab because of China-only data, all eyes have turned to the next China-developed PD-1 therapy in line at the FDA.

Related Keywords

,Coherus ,Junshi Biosciences ,Pd 1 L1 ,Head And Neck Cancer ,Immuno Oncology ,China ,Sfda Inspection ,Sanofi ,Innovent Biologics ,Checkpoint Inhibitors ,Asia ,Manufacturing ,Fierce Pharma Homepage ,Pharma ,